lncRNA LA16c‑313D11.11 modulates the development of endometrial cancer by binding to and inhibiting microRNA‑205‑5p function and indirectly increasing PTEN activity

  • Authors:
    • Weijuan Xin
    • Shuting Zhao
    • Xuesong Han
    • Peng Zhao
    • Hui Yu
    • Xiaodong Gao
    • Ping Li
    • Qianyu Wu
    • Jingxin Ding
    • Keqin Hua
  • View Affiliations

  • Published online on: April 13, 2020     https://doi.org/10.3892/ijo.2020.5046
  • Pages: 355-363
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to determine the competitive endogenous RNA (ceRNA) network associated with long‑coding RNA (lncRNA) LA16c‑313D11.11 in endometrial cancer (EC). Initially, the expression levels of LA16c‑313D11.11 in 60 EC tissues, 20 atypical hyperplasia endometrium (EAH) tissues and 20 normal endometrium tissues was determined. MicroRNA (miRNA/miR)‑205‑5p mimics and LA16c‑313D11.11 mimics were transfected into HEC‑1A and Ishikawa cells. The expression levels of miR‑205‑5p, LA16c‑313D11.11 and their target proteins were assessed using reverse transcription‑quantitative PCR or western blot analysis. Flow cytometry, Cell Counting kit‑8 assays, Transwell migration assays and wound healing assays were performed to assess the effects of LA16c‑313D11.11 and miR‑205‑5p on the migration and proliferation of tumor cells in vitro. The expression levels of LA16c‑313D11.11 and phosphatase and tensin homolog deleted on chromosome ten (PTEN) in human EAH and EC tissues were significantly decreased, whereas the expression levels of miR‑205‑5p in EAH and EC tissues were significantly increased, compared with the normal endometrium tissues. The expression of LA16c‑313D11.11 in human EC tissues negatively correlated with the expression of miR‑205‑5p. Additionally, the overexpression of LA16c‑313D11.11 significantly reduced the invasion, migration and viability of HEC‑1A and Ishikawa cells in vitro. LA16c‑313D11.11 was shown to regulate the expression of PTEN, and the invasion, migration and viability of HEC‑1A and Ishikawa cells, through its microRNA response element to compete for microRNA‑205‑5p. LA16c‑313D11.11 was also shown to modulate the PI3K/AKT signaling pathway. Therefore, LA16c‑313D11.11 acts as an effective ceRNA associated with a microRNA‑205‑5p‑PTEN axis. LA16c‑313D11.11 may inhibit the development and progression of EC by acting as a sponge of miR‑205‑5p, thus indirectly increasing the expression of PTEN.
View Figures
View References

Related Articles

Journal Cover

July-2020
Volume 57 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Xin W, Zhao S, Han X, Zhao P, Yu H, Gao X, Li P, Wu Q, Ding J, Hua K, Hua K, et al: lncRNA LA16c‑313D11.11 modulates the development of endometrial cancer by binding to and inhibiting microRNA‑205‑5p function and indirectly increasing PTEN activity. Int J Oncol 57: 355-363, 2020
APA
Xin, W., Zhao, S., Han, X., Zhao, P., Yu, H., Gao, X. ... Hua, K. (2020). lncRNA LA16c‑313D11.11 modulates the development of endometrial cancer by binding to and inhibiting microRNA‑205‑5p function and indirectly increasing PTEN activity. International Journal of Oncology, 57, 355-363. https://doi.org/10.3892/ijo.2020.5046
MLA
Xin, W., Zhao, S., Han, X., Zhao, P., Yu, H., Gao, X., Li, P., Wu, Q., Ding, J., Hua, K."lncRNA LA16c‑313D11.11 modulates the development of endometrial cancer by binding to and inhibiting microRNA‑205‑5p function and indirectly increasing PTEN activity". International Journal of Oncology 57.1 (2020): 355-363.
Chicago
Xin, W., Zhao, S., Han, X., Zhao, P., Yu, H., Gao, X., Li, P., Wu, Q., Ding, J., Hua, K."lncRNA LA16c‑313D11.11 modulates the development of endometrial cancer by binding to and inhibiting microRNA‑205‑5p function and indirectly increasing PTEN activity". International Journal of Oncology 57, no. 1 (2020): 355-363. https://doi.org/10.3892/ijo.2020.5046